… to patients receiving standard of care alone for the treatment of stage IV pancreatic cancer.
Further prospective cost-effectiveness studies are mandatory to reevaluate our findings. …

… Total cost was calculated for each patient from index date until end of follow-up for individual
cost components using administrative data, including systemic therapy drug acquisition, …

… fraction of patients with pancreatic cancer, the potential exists for … pancreatic cancer.To date,
there are no published studies on the cost-effectiveness of immunotherapy in the pancreatic …

… cost-effectiveness of these five treatment options in mHSPC from the US payer perspective
to guide treatment … To our knowledge, this study is the first cost-effectiveness analysis of all …

… : Maintenance therapy with the PARP inhibitor olaparib for metastatic pancreatic cancer (MPC…
We aimed to evaluate the cost-effectiveness of maintenance olaparib for MPC from the US …

… We sought to evaluate the cost effectiveness of this strategy. … cases in the population, but
both the cost effectiveness of this … : to evaluate the cost effectiveness of this early detection …

… viability as a clinical treatment option. This work aims to evaluate the cost-effectiveness of
olaparib as a maintenance treatment for metastatic pancreatic cancer from the perspective of …

… Incremental cost-effectiveness ratios were calculated as part of the cost-effectiveness
analysis. A meta-analysis was performed using random-effects models and Trial sequential …

… understanding the economic impact of therapies relative to their clinical … cost-effectiveness
of adjuvant treatments (FOLFIRINOX vs GemNab) for adults with resectable pancreatic cancer …

… As in the USR branch, they received an exploratory laparotomy, those with visually resectable
disease were resected, and those with unresectable disease received systemic therapy. …